Group One Trading
OVID icon

Group One Trading’s Ovid Therapeutics OVID Stock Holding History

Group One Trading’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.4K Buy
+13,246
New +$23.7K ﹤0.01% 5685
2025
Q4 		– Sell
-188,295
Closed -$290K – 8885
2025
Q3 		$245K Buy
+188,295
New +$163K ﹤0.01% 4457
2022
Q4 		– Sell
-1,532
Closed -$3K – 7872
2022
Q3 		$3K Sell
1,532
-36
-2% -$75 ﹤0.01% 7038
2022
Q2 		$3K Sell
1,568
-1,500
-49% -$3.63K ﹤0.01% 7318
2022
Q1 		$10K Sell
3,068
-9,838
-76% -$30.9K ﹤0.01% 7162
2021
Q4 		$41K Sell
12,906
-41,401
-76% -$142K ﹤0.01% 6478
2021
Q3 		$182K Sell
54,307
-11,394
-17% -$41.5K ﹤0.01% 5271
2021
Q2 		$257K Sell
65,701
-100,655
-61% -$397K ﹤0.01% 4956
2021
Q1 		$669K Buy
166,356
+100,721
+153% +$335K ﹤0.01% 3702
2020
Q4 		$152K Buy
65,635
+65,573
+105,763% +$306K ﹤0.01% 4268
2020
Q3 		$0 Sell
62
-8,338
-99% -$55.8K ﹤0.01% 6425
2020
Q2 		$62K Buy
+8,400
New +$39.3K ﹤0.01% 4225

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Group One Trading's OVID Position: Q1 2026 in Review

Group One Trading opened a new position in Ovid Therapeutics (OVID) in Q1 2026: 13,246 shares worth $29.4K. The stake represents ﹤0.01% of the portfolio and ranks #5685 among its holdings. This is a return to the name: Group One Trading previously reported a position in OVID as recently as Q3 2025.

Group One Trading first reported a position in OVID in Q2 2020 and has held it in 12 quarters since. The position peaked at $669K in Q1 2021. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Group One Trading held 13,246 shares of Ovid Therapeutics worth $29.4K as of Q1 2026.
  • Ovid Therapeutics was a new Group One Trading position in Q1 2026.
  • Ovid Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5685 holding.
  • Group One Trading first reported a position in Ovid Therapeutics in Q2 2020 and has held it in 12 quarters since.
  • Group One Trading's Ovid Therapeutics position peaked at $669K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.